Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore effective ways to boost your credit card point accumulation. Learn strategies to earn more rewards with every purchase.
21,988 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A major fund sold almost 230k ANIP shares in Q1, triggering volatility in the pharma stock. This article breaks down ...
TriSalus investors are eyeing the Q1 2026 earnings update to gauge cash runway, pipeline progress, and milestone-driv...
SoundHound AI stock has slipped in 2026, leaving investors to weigh risk against opportunity. This guide breaks down ...
Resolute Holdings stock soars can signal a potent momentum move. This guide breaks down the drivers, evaluates sustai...
A Tuesday pullback in COP shares left investors weighing oil prices, broker notes, and the long-term outlook for ener...
A major enterprise contract could transform D-Wave from a hardware play into a recurring-revenue champion. This artic...
Bitcoin has entered a stark profit-and-loss juncture, with a growing share of the supply losing money as prices hover...
Institutional moves can hint at mood, but they don’t guarantee gains. A large stake in Capri Holdings by DME Capital ...
Markets can overreact to short-term costs even when the long-term AI story is intact. This article outlines one overs...
When a big fund buys in after a sharp drop, it sends a message about confidence and risk. This piece breaks down what...
Bitcoin cleared the $70,000 barrier and moved toward $74,000, sparking bets on higher bitcoin’s next price targets as...